

BIRCH, STEWART, KOLASCH & BIRCH, LLP

TERRELL C. BIRCH
RAYMOND C. STEWART
JOSEPH A. KOLASCH
JAMES M. SLATTERY
BERNARD L. SWEENEY*
MICHAEL K. MUTTER
CHARLES GORENSTEIN
GERALD M. MURPHY, JR.
LEONARD R. SVENSSON
TERRY L. CLARK
ANDREW D. MEIKLE
MARC S. WEINER
JOE MCKINNEY MUNCY
ROBERT J. KENNEY
DONALD J. DALEY
JOHN W. BAILEY
JOHN A. CASTELLANO, III
GARY D. YACURA

OF COUNSEL:
HERBERT M. BIRCH (1905-1996)
ELLIOT A. GOLDBERG*
WILLIAM L. GATES*
EDWARD H. VALANCE
RUPERT J. BRADY (RET.)*
F. PRINCE BUTLER
R. S. WHISENHUNT

NOT ADMITTED TO A BAR OTHER THAN VA.

INTELLECTUAL PROPERTY LAW
8110 GATEHOUSE ROAD
SUITE 500 EAST
FALLS CHURCH, VA 22042-1210
USA
(703) 205-8000

FAX: (703) 205-8050
(703) 698-8590 (C IV)

e-mail: mailroom@bskb.com
web: http://www.bskb.com

CALIFORNIA OFFICE:
COSTA MESA, CALIFORNIA

THOMAS S. AUCHTERLONK
JAMES T. ELLER, JR.
SCOTT L. LOWE
MARK J. NUEL, Ph.D.
D. RICHARD ANDERSON
PAUL C. LEWIS
MARK W. MILSTEAD*
RICHARD J. GALLAGHER
JAYNE M. SAYDAH*

REG. PATENT AGENTS:
FREDERICK R. HANDREN
MARYANNE ARMSTRONG, Ph.D.
MAKI HATSUMI
MIKE S. RYU
CRAIG A. McROBBIE
GARTH M. DAHLEN, Ph.D.
LAURA C. LUTZ
ROBERT E. GOOZNER, Ph.D.
HYUNG N. SOHN
MATTHEW J. LATTIG
ALAN PEDERSEN-GILES
C. KEITH MONTGOMERY
TIMOTHY R. WYCKOFF
KRISTI L. RUPERT, Ph.D.
LARRY J. HUME
ALBERT LEE
HRAYR A. SAYADIAN, Ph.D.

1c490 U.S. PTO
09/655336
09/05/00

Date: September 5, 2000

Docket No.: 1422-437P

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This is a Request for filing a ☐ continuation ☒ divisional
☐ continuation-in-part application under 37 C.F.R. § 1.53(b) of
pending prior Application No. 09/403,486 filed on October 22,
1999, the entire contents of which are hereby incorporated by
reference,
by

Tomoko UEDA, Yukiko NAGATO, Yukiko TANAKA, Tsutomu OKUBO, Kanari
KOBAYASHI, Nobuyuki AOI, Seiji SHU, Lekh Raj JUNEJA

for

COMPOSITION COMPRISING THEANINE

1. ☒ Enclosed is an application consisting of specification,
claims, declaration and drawings/photographs (if
applicable).
2. ☒ The filing fee has been calculated as follows:

			LARGE ENTITY	SMALL ENTITY
BASIC FEE			\$690.00	\$345.00
	NUMBER FILED	NUMBER EXTRA	RATE FEE	RATE FEE
TOTAL CLAIMS	15-20 =	0	x 18 = \$0.00	x 9 = \$0.00
INDEPENDENT CLAIMS	2-3 =	0	x 78 = \$0.00	x 39 = \$0.00
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED			+ \$260.00	+ \$130.00
TOTAL			\$690.00	\$0.00

3. ☒ A check in the amount of \$690.00 to cover the filing fee and recording fee (if applicable) is enclosed.
4. ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. A triplicate copy of this request is enclosed.
5. Amend the specification by inserting before the first line thereof the following:
- a. ☐ --This application is a ☐ continuation ☐ divisional ☐ continuation-in-part of co-pending Application No. 09/403,486, filed on October 22, 1999, the entire contents of which are hereby incorporated by reference.--
- b. ☒ --This application is a ☐ continuation ☒ divisional ☐ continuation-in-part of co-pending Application No. 09/403,486, filed on October 22, 1999. Application No. 09/403,486 is the national phase of PCT International Application No. PCT/JP99/00784 filed on February 23, 1999 under 35 U.S.C. § 371. The entire contents of each of the above-identified applications are hereby incorporated by reference.--
6. ☒ Enclosed is/are five (5) sheet(s) of formal drawings and/or photographs.

7. ☐ A statement claiming small entity status was filed in prior Application No. 09/403,486 on _____. See the attached copy of the statement claiming small entity status.
8. ☒ The prior application is assigned to Taiyo Kagaku Co., Ltd..
9. ☒ A Preliminary Amendment is enclosed.
- 10a. ☐ Priority of Application No(s). _____ filed in _____ on _____ is/are claimed under 35 U.S.C. § 119. See attached copy of the Letter claiming priority filed in the prior application on _____.
- 10b. ☒ Priority of International Appln. PCT/JP99/00784 filed on February 23, 1999 under the Patent Cooperation Treaty and Japanese Application Nos. 10-57470; 10-142119; 10-234968; and 10-330207 filed in Japan on February 23, 1998; May 8, 1998; August 6, 1998; and November 5, 1998, respectively, under 35 U.S.C. § 119 are hereby reclaimed.
11. ☒ An Information Disclosure Statement and PTO-1449 form(s) are attached hereto for the Examiner's consideration.
12. ☒ Address all future communications to:


BIRCH, STEWART, KOLASCH & BIRCH, LLP
P.O. Box 747
Falls Church, VA 22040-0747
Telephone: (703) 205-8000

or
Customer No. 2292
13. ☐ An extension of time for _____ () month(s) until _____ has been submitted in parent Application No. 09/403,486 in order to establish co-pendency with the present application.
14. ☐ Also enclosed herewith is the following:

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Gerald M. Murphy, Jr., #28,977


GMM/REG/gml
1422-437P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachments

(Rev. 06/07/2000)

20250606 14:22:43

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tomoko UEDA et al.
Serial No: NEW-Rule 53(b) Div.
of 09/403,486 Group: Unassigned
Filed: September 1, 2000 Examiner: Unassigned
For: COMPOSITION COMPRISING THEANINE

PRELIMINARY AMENDMENT

Assistant Commissioner of Patent
Washington, D.C. 20231

September 5, 2000

Sir:

The following preliminary amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE CLAIMS:

Please cancel claims 1-7 without prejudice to or disclaimer of the subject matter contained therein.

Please add the following claims:

--8. A method for treating an individual in need of suppressing or ameliorating a symptom accompanying diminished homeostasis, comprising:

administering a composition comprising theanine to the individual in need thereof.

9. The method according to claim 8, wherein the symptom accompanying diminished homeostasis is obesity.

10. The method according to claim 8, wherein the symptom accompanying diminished homeostasis is anxiogenic symptoms.

11. The method according to claim 8, wherein the symptom accompanying diminished homeostasis is premenstrual syndrome.

12. The method according to claim 8, wherein the symptom accompanying diminished homeostasis is sensitivity to cold.

13. The method according to claim 8, wherein the symptom accompanying diminished homeostasis is menopausal disorders.

14. The method according to claim 8, wherein the symptom accompanying diminished homeostasis is sleep disorders.

15. The method according to claim 8, wherein the symptom accompanying diminished homeostasis is autonomic imbalance.

16. The method according to claim 8, wherein the composition is a food composition or a pharmaceutical composition.

17. The method according to claim 8, wherein the composition further comprises a mineral.

18. The method according to claim 17, wherein the mineral is one or more selected from the group consisting of iron, magnesium, copper, zinc, selenium, calcium, potassium, manganese, chromium, iodine, molybdenum, nickel, vanadium, and salts thereof.

19. A method for improving metal taste of a mineral composition wherein one or more minerals are present in an amount sufficient to cause metal taste, comprising:

adding theanine to the mineral composition.

20. The method according to claim 19, wherein the mineral is selected from the group consisting of iron, magnesium, copper, zinc, selenium, calcium, potassium, manganese, chromium, iodine, molybdenum, nickel, vanadium and salts thereof.

21. The method according to claim 17, wherein the symptom accompanying diminished homeostasis is selected from the group consisting of anxiogenic symptoms, premenstrual syndrome, sensitivity to cold, menopausal disorders, sleep disorders and autonomic imbalance.

22. The method according to claim 18, wherein the symptom accompanying diminished homeostasis is selected from the group consisting of anxiogenic symptoms, premenstrual syndrome, sensitivity to cold, menopausal disorders, sleep disorders and autonomic imbalance.--

REMARKS

Claims 8-22 are now pending in this application. The additional claims are supported by and throughout the present specification (see Table I). Accordingly, no new matter has been added.

Table I

Claim Number	Specification page
Claim 8	page 7, line 16 to page 9, line 4
Claim 9	page 9, lines 5-24; Figure 2
Claim 10	page 9, line 25 to page 11, line 8
Claim 11	page 11, line 9 to page 12, line 16
Claim 12	page 12, lines 17-25
Claim 13	page 13, lines 1-15
Claim 14	page 13, lines 16-19; Figure 5
Claim 15	page 8, lines 8-13; page 11, line 9 to page 13, line 19
Claim 16	page 13, line 20 to page 17, line 7
Claim 17	page 6, lines 14-21; page 17, line 22 to page 18, line 17
Claim 18	page 6, line 21 to page 7, line 3; page 17, line 22 to page 18, line 4
Claim 19	Page 19, lines 24 to page 21, line 22
Claim 20	page 6, line 21 to page 7, line 3; page 17, line 22 to page 18, line 4
Claims 21 and 22	See support for claims 9-15 above

In view of the foregoing remarks, Applicants respectfully request prosecution on the merits.

The present application is a divisional/continuation of parent application Serial No. 09/403,486, filed October 22, 1999, which is filed to pursue subject matter not covered or specifically claimed in the allowed claims of the parent application.

If the Examiner has any questions concerning this application, he is requested to contact Robert E. Goozner, Ph.D. (Reg. No. 42,593) at (703) 205-8000 in the Washington, D.C. area.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By: 

Gerald M. Murphy, Jr.
Reg. No. 28,977

Post Office Box 747
Falls Church, VA 22040-0747
(703) 205-8000


GMM/REG/gml

DESCRIPTION

COMPOSITION COMPRISING THEANINE

5 TECHNICAL FIELD

The present invention relates to a
theanine-containing composition which can be used for a
food composition, a pharmaceutical composition, and the
like, for suppressing and ameliorating various symptoms
10 accompanying diminished homeostasis, such as obesity,
anxiogenic symptoms, premenstrual syndrome, sensitivity to
cold, menopausal disorders, sleep disorders and autonomic
imbalance. Further, the present invention relates to a
mineral composition in which a peculiar metal taste is
15 reduced.

BACKGROUND ART

Conventionally, various symptoms accompanying
diminished homeostasis, such as obesity, anxiogenic
20 symptoms, premenstrual syndrome, sensitivity to cold,
menopausal disorders, sleep disorders and autonomic
imbalance, have been treated by symptomatic
chemotherapies. A number of kinds of such symptoms,
disorders, and the like can often develop concurrently
25 with aging. In such case, great cautions should be

exerted in prescribing drugs appropriate for individual symptoms, e.g., hormones, kampo medicines, tranquilizers, and the like, in combination, because unexpected adverse reactions can occur. There is therefore demand for a very safe composition, such as a food composition, for mitigating and ameliorating such complicating symptoms without the aid of drugs.

Although a wide variety of causes are involved in the pathogenesis of these diseases, it is a key to their prevention and treatment to improve our dietary life. In other words, imbalanced nutrient intake also contributes to the development of the aforementioned diseases, despite the recent enrichment of our dietary life. Nutrition surveys have demonstrated that the minimum requirements are not satisfied for some minerals. Against this background, minerals have recently been added to foods, beverages, supplements, nutrition enhancers, and the like; however, their peculiar metal tastes limit the amount of their addition or reduce their commercial value.

Therefore, an object of the present invention is to provide a composition for suppressing and ameliorating the above symptoms. Particularly, it is to provide a composition having high safety, the composition of which the method of administration is simple, even in the case of the complicated symptoms. Further, it is to provide a

mineral composition, of which a peculiar metal taste is reduced and administration is made easy. These and other objects of the present invention will be apparent from the following description.

5

DISCLOSURE OF INVENTION

As a result of intensive studies in view of solving the above problems, the present inventors have found that theanine has marked effects in suppression and amelioration against various symptoms. In this case, not only the composition comprising theanine, but also the composition comprising a mineral as well as theanine would also allow to provide mineral supplement. The present inventors have found that this composition has a reduced peculiar metal flavor, so that they have found a mineral composition to easily allow mineral supplement. Based on these findings, the present inventors have completed the present invention.

10

15

20

Specifically, in essence, the present invention pertains to:

[1] a composition for suppressing or ameliorating a symptom accompanying diminished homeostasis, comprising theanine; and

[2] a mineral composition comprising theanine and a mineral.

25

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph showing the influence of theanine on the body weight increase of young female rats. In the figure, \square are data for the inventive products; and \bullet are control data, respectively.

Figure 2 is a graph showing the effect for obesity suppression of theanine in the ovariectomized rats. In the figure, \square are data for the inventive products; and \bullet are control data, respectively.

Figure 3 is a graph showing the body temperature elevation effect by theanine. The abscissa of the graph shows the passage of period of time (minutes) after administration of a theanine-containing capsule or placebo, and the ordinate is the temperature of tip finger.

Figure 4 is a graph showing the amount of spontaneous exercise for theanine-administered group and non-administrated group (control group), respectively.

Figure 5 is a graph showing sleeping time for theanine-administered group, non-applying group, and non-administered group, respectively.

BEST MODE FOR CARRYING OUT THE INVENTION

1. Theanine-Containing Composition

Theanine, formulated in the theanine-containing

composition of the present invention, is a glutamic acid derivative contained in tea-leaves, which is the main component of deliciousness (umami) of tea. It is also used as a food additive for seasoning. Regarding its safety, there are no dead cases of animals receiving an oral administration of 2 g/kg in acute toxicity test with mice, nor was there any abnormal finding in gross condition or body weight. As described above, the theanine is an extremely safe substance.

The method for detecting theanine in the composition of the present invention is not particularly limited, and preference is given to the method comprising derivatizing with ortho-phthalaldehyde (OPA) at a pre-column, thereafter separating by high performance chromatography with an ODS column, and detecting and quantifying theanine with a fluorescence detector.

Examples of methods for preparing theanine used in the present invention include an organic synthesis method [*Chem. Pharm. Bull.*, 19(7), 1301-1307 (1971)]; fermentation methods (Japanese Patent Laid-Open Nos. Hei 5-68578 and Hei 5-328986); or modification methods thereof using an ethylamine derivative, such as ethylamine hydrochloride, in place of ethylamine; a method comprising reacting pyroglutamic acid with ethylamine hydrochloride (Japanese Patent Laid-Open No. Hei 9-263573); a plant cell

culture method (Japanese Patent Laid-Open No. Hei 5-123166); and a method using extraction from tea-leaves, with preference given to the fermentation methods, which permit the obtainment of theanine in large amounts at low costs. The term "tea-leaves" as used herein refers to green tea, oolong tea, black tea, and the like.

In addition, any of L-theanine, D-theanine and DL-theanine are usable, among which the L-form is preferred in the present invention, because it is approved as a food additive, and it is economically utilizable. In addition, the theanine used in the present invention may be of any forms, such as purified products, crudely purified products, extracts, and the like.

The composition of the present invention may further comprise a mineral. The composition comprising minerals is more preferable, because it can supplement essential elements and trace essential elements, which tend to be deficient in living bodies. The mineral content in the composition, for example, is preferably from 0.0001 to 99.9% by weight and more preferably 0.01 to 99.9% by weight. As described in detail in the section of "Mineral Composition" below, the term "minerals" as used herein refers to metals essential for the maintenance and regulation of living bodies, such as iron, magnesium, copper, zinc, selenium, calcium, potassium, manganese,

chromium, iodine, molybdenum, nickel and vanadium, or salts thereof, wherein their content is calculated as the amount of these metal elements. The mineral may be constituted by of a single metal element or a plurality of metal elements.

In addition, the theanine can be used in combination with other ingredients. The other ingredients are not particularly limited, and examples thereof include herbs, such as Saint John's-wort and chamomile; kampo medicinal plants, such as *Gymnema sylvestre*, *Garcinia cambogia*, *Eucommia ulmoides* and ginseng, or extracts thereof; animal extracts, such as placenta extract; functional materials, such as dietary fiber and soybean peptide; vitamins; and dieting sweeteners, with preference given to functional materials, such as dietary fiber and soybean peptide.

The composition of the present invention comprising theanine has suppressive effect and ameliorating effect on various diseases. For the purpose of suppressing and ameliorating symptoms accompanying diminished homeostasis, concretely for obesity suppression, suppression of anxiogenic symptoms, suppression of premenstrual syndrome, amelioration of sensitivity to cold, amelioration of menopausal disorders, amelioration of sleep disorders and amelioration of autonomic imbalance, the composition of the present invention can be used.

The term "diminished homeostasis" as used in the present invention is defined as a state wherein the potential of an organism for stably maintaining its morphological and physiological conditions in normal ranges using the nervous, endocrine, circulatory and immune systems, while undergoing various external and internal changes, to ensure survival as an individual has been diminished. Specific symptoms include bad physical condition and mental anxiety due to hormone hypersecretion, deficiency, and the like, and autonomic imbalance symptoms, such as stiff shoulders, headache, vertigo, sensitivity to cold, irritation, palpitation, short breath, dyspnea, numbness and insomnia.

The amount of administration of the theanine for sufficiently exhibiting the suppressive effect for diminished homeostasis is preferably from 0.2 to 2,000 mg/kg•day, more preferably from 0.2 to 300 mg/kg•day. However, since there are individual differences in the kinds of symptoms and the degree of progression, the amount of administration of the theanine in the present invention is not limited to the ranges specified above.

The content of the theanine in the composition of the present invention may be appropriately adjusted depending upon the concrete symptoms, ages, number of

administration, and the like. For example, the content of the theanine in the composition is preferably from 0.00025 to 100% by weight, more preferably 0.005 to 100% by weight.

5 The term "obesity" as used in the present invention refers to a form of obesity accompanied by complications due to over-accumulation of fat, which is caused by overeating, inappropriate eating style, lack of exercise, heredity, thermogenesis disorders or an unidentified
10 cause.

 As for suppressing an effect for obesity, a satisfactory effect can be obtained when the theanine is preferably administered at 0.3 mg/kg•day or more, and as the amount of the administration is increased, its effect
15 is further enhanced. Since the theanine is a highly safe substance, the amount of administration is not particularly limited. It is desired that the amount of administration does not exceed the level of 2,000 mg/kg•day. Therefore, the amount of administration
20 of the theanine for sufficiently exhibiting the suppressive effect for obesity is preferably from 0.3 to 2,000 mg/kg•day, more preferably from 0.3 to 100 mg/kg•day, still more preferably from 0.3 to 50 mg/kg•day.

25 The composition of the present invention can be used

to suppress anxiogenic symptoms. The term "anxiogenic symptoms" as used in the present invention refers to a form of anxiogenic symptoms due to continuous or habitual intake of a methylxanthine derivative or an unidentified
5 cause. Continuous or habitual intake of a methylxanthine derivative is said to promote anxiety symptoms, which can lead to panic disorders characterized by the sudden development of severe anxiety together with palpitation, vertigo and other symptoms; continuous or habitual intake
10 of a methylxanthine derivative is said to be a cause of panic disorders. The methylxanthine derivative mentioned here is exemplified by caffeine, theophylline and theobromine. Forms of methylxanthine derivatives are not particularly limited, and they include natural or
15 synthetic purified products, foods and pharmaceuticals supplemented therewith, coffee, cocoa, green tea, fermented teas, such as black tea, semi-fermented teas, such as oolong tea, or processed products therefrom.

As for suppressing anxiogenic symptoms, a
20 satisfactory effect can be obtained when the theanine is preferably administered at 0.3 mg/kg•day or more, and as the amount of administration is increased, its effect is further enhanced. Although there is no upper limit for the amount of administration of the theanine, it is
25 generally preferable that the amount of administration

does not exceed about 300 mg/kg•day, when taken into consideration of the distinctive taste and economic advantages of the theanine. Therefore, the amount of administration of the theanine for sufficiently exhibiting the suppressive effect for anxiogenic symptoms is preferably from 0.3 to 300 mg/kg•day, more preferably from 0.3 to 30 mg/kg•day, and still more preferably from 0.3 to 3 mg/kg•day.

The term "premenstrual syndrome (PMS)" as used in the present invention is defined as a series of various symptoms that can interfere with daily life of the patient, due to a hormone imbalance, occurring in the high basal body temperature phase, i.e., the ovarian corpus lutea stage, starting about 2 weeks before menstruation in females.

More than 150 symptoms can be developed, including physical symptoms, such as sleepiness, fatigability, stiff breasts, painful breasts, likelihood to have acne, chapped skin, bad spread of cosmetics, increased vaginal discharge, inability to take smooth body action, allergic symptoms, headache, head stuffiness, stiff shoulders, vertigo, limb coldness, abdominal pain, lower abdominal pain, lower abdominal stiffness, lumbago, swelling, thirst, constipation, diarrhea, increased appetite, decreased appetite and food preference change; mental

symptoms, such as depressive state, spiritlessness,
irritation, aggressiveness, faintheartedness, maudlinness,
solitariness, loneliness, anxiety, psychological lift,
inability to concentrate, decreased work efficiency,
5 increased sexual desire and decreased sexual desire; and
social symptoms, such as autism, mysophobia, inability to
manage one's health, repugnance to menstruation, weariness
of doing anything, inability to work as usual, repugnance
to being female, quarrels with others, staying at home,
10 craving to be alone, craving to waste money, railing at
one's families and friends, and unsociableness, without
being limited thereto.

The amount of administration of the theanine for
sufficiently exhibiting the suppressive effect for
15 premenstrual syndrome is preferably from 0.2 to
200 mg/kg•day, more preferably from 0.5 to 50 mg/kg•day.

The term "sensitivity to cold" as used in the present
invention refers to a subjective symptom of pain of cold
in the body and each sites of the body, which is a
20 relatively chronic recognition of cold, not caused by
drastic external causes.

The amount of administration of the theanine for
sufficiently exhibiting the amelioration effect for
sensitivity to cold is preferably from 0.2 to
25 200 mg/kg•day, more preferably from 0.5 to 50 mg/kg•day.

The term "menopausal disorders" as used herein is defined as a series of health condition changes occurring when gonadotropin is hypersecreted as the amount of progesterone and estrogen secreted decreases. Specific
5 symptoms include autonomic abnormalities, such as hot sensation, flushing, palpitation, excess sweating and sensitivity to cold; mental symptoms, such as depression, fretfulness, anxiety, insomnia, tinnitus, numbness, diarrhea, pollakiuria, hypomnesia and diminished judgment;
10 and other symptoms, such as stiff shoulders, lumbago and malaise.

The amount of administration of the theanine for sufficiently exhibiting the amelioration effect for menopausal disorders is preferably from 0.2 to
15 200 mg/kg•day, more preferably from 0.5 to 50 mg/kg•day.

The amount of administration of the theanine for sufficiently exhibiting the amelioration effect for sleep disorders is preferably from 0.2 to 200 mg/kg•day, more preferably from 0.5 to 50 mg/kg•day.

20 Regarding the embodiment of use of the composition of the present invention, it can advantageously be used for a food composition or a pharmaceutical composition. The term "food composition" as used in the present invention encompasses theanine-containing food additives, as well as
25 theanine-containing foods. When used for a food

composition, the composition of the present invention may be prepared by, for example, formulating the theanine in any one of the foods shown below.

Specifically, the theanine can be formulated in dry
5 foods, supplements, and liquid foods, such as soft drinks, mineral water, luxury beverages and alcoholic beverages. Beverages which may be mentioned herein are not particularly limited, and examples thereof include teas, such as green tea, oolong tea, black tea and herb tea,
10 fruit juice concentrates, reconstituted juice concentrates, fresh juices, mixed fruit juices, fruit grain-containing fruit juice, fruit juice-containing beverages, mixed fruit/vegetable juice, vegetable juice, carbonated beverages, soft drinks, milk beverages,
15 Japanese sake, beer, wine, cocktails, shochu and whiskey. In addition, crude drugs, herbs, amino acids, vitamins and other materials and ingredients which are acceptable for foods may be used together in combination with the theanine. Crude drugs used herein are not particularly
20 limited, and examples thereof include Japanese valerian, Japanese angelica root, peony root, moutan, ginseng, and the like, which are effective in keeping a good hormone balance in females. Herbs are not particularly limited, and examples thereof include anise, carrot seed, clove,
25 coriander, cypress, cinnamon, juniper, ginger, sweet

orange, pine needle, basil, patchouli, bitter orange,
fennel, black pepper, bay, peppermint, bergamot, mandarin,
myrrh, lemongrass, rosemary, grapefruit, cedarwood,
citronella, sage, thyme, tea tree, violet leaf, vanilla,
5 hyssop, eucalyptus, lime, lemon, ylang-ylang, cardamon,
clary sage, jasmine, geranium, chamomile, Bulgarian rose,
rose, olibanum, lavender, chamomile, geranium, sandalwood,
neroli, verbena, petigrain, vetiver, marjoram, lemon balm
(*Melissa officinalis*), rosewood, Saint John's-wort, Saint
10 John's-wort and kawakawa, with preference given to
peppermint, bergamot, ylang-ylang, geranium, chamomile,
lavender, Saint John's-wort and kawakawa, all of which
have sedative and relaxing effects. The forms of these
herbs are not particularly limited, and examples thereof
15 include extract, essential oil and herb tea. The amino
acids used are not limited, and examples thereof include
glutamine, glutamic acid, inosinic acid, alanine,
arginine, aspartic acid, threonine, serine, γ -aminobutyric
acid, taurine, thiotaurine and hypotaurine. The vitamins
20 used are not particularly limited, and examples thereof
include vitamin A, vitamin B₁, vitamin B₂, vitamin B₆,
vitamin B₁₂, vitamin C, vitamin D, vitamin E, vitamin K,
folic acid, nicotinic acid, lipoic acid, pantothenic acid,
biotin and ubiquinone, as well as derivatives thereof. In
25 addition, other useful substances include aloe, royal

jelly, melatonin, placenta, propolis, isoflavone, soybean lecithin, egg yolk lecithin, egg yolk oil, chondroitin, cacao mass, collagen, vinegar, chlorella, spirulina, ginkgo leaf, green tea, tochu tea, Chinese wolfberry tea, oolong tea, mulberry leaf, *Rubus suavissimus*, banaba tea, unsaturated fatty acids, saccharides such as oligosaccharides, bifidobacteria, fungi such as red koji, mushrooms such as *Agaricus blazei*, *Agaricus blazei*, ganoderma and *Grifola frondosa*, fruits such as blueberry, prune, grape, olive, *ume* and citruses, seeds such as peanuts, almonds, sesame and pepper, vegetables such as green pepper, chili, Welsh onion, pumpkin, melon, carrot, great burdock, jute leaf (*Corchorus capsularis*), garlic, perilla, wasabi, tomato, scallion, leaf vegetables, tubers and pulses, seaweeds such as wakame, fishes, animal meat/poultry/whale meat and cereals, as well as extracts, dry products, crudely purified products, purified products, processed products, fermented products and other products therefrom.

When the theanine-containing composition of the present invention is used for a pharmaceutical composition, its form is not particularly limited, and it may be prepared as any one of solutions, suspensions, powders, molded solids, and the like. Therefore, the theanine-containing composition of the present invention

can be provided as capsules, tablets, powders, granules, drinks, and the like. In addition, the theanine-containing composition of the present invention can be used in combination with other pharmaceuticals.

5 The pharmaceutical composition is expected to have the same effects as those of the aforementioned food composition.

The method for preparing the composition of the present invention is not particularly limited, and general
10 preparation methods for foods and pharmaceuticals may be used, including a method comprising mixing theanine and other ingredients in a powder; a method comprising dissolving theanine and other ingredients in a solvent to yield a mixed solution; a method comprising freeze-drying
15 the resulting mixed solution; and a method comprising spray-drying the mixed solution. For example, the composition can be obtained by formulating theanine and other ingredients with commonly known excipients, carriers, binders, stabilizers, and the like.

20

2. Mineral Composition

The mineral composition of the present invention comprises theanine and a mineral. The mineral used in the present invention, which is the same as that described in
25 the above section of Theanine-Containing Composition, is

an essential metal for maintenance and regulation of living bodies, such as iron, magnesium, copper, zinc, selenium, calcium, potassium, manganese, chromium, iodine, molybdenum, nickel and vanadium. Its form includes salts, oxides, protein complexes, or complexes of degraded products thereof; polysaccharides or complexes of degraded products thereof; other processed starch complexes; cyclodextrin complexes; metal enzymes comprising minerals, such as superoxide dismutase, glutathione peroxidase and acidic phosphatase; metal-activated enzymes such as phosphoglucomutase; enzymes and coenzymes containing a metal at sites other than the active center sites, and the like. These minerals may be those which are naturally occurring, and preferably those which are isolated and purified by a known method to increase its mineral content. Here, one embodiment of the form of the mineral will be shown.

The iron compound includes iron, ferrous sulfate (dry), ferrous sulfate (crystalline), iron citrate, ferrous gluconate, ferrous pyrophosphate, ferric pyrophosphate, ferrous pyrophosphate solution, ferric pyrophosphate solution, ferric chloride, iron lactate, iron ammonium citrate, diiron trioxide, ferritin, transferrin, ovotransferrin, heme iron, and the like. The magnesium compound includes magnesium carbonate, magnesium

sulfate, magnesium chloride, magnesium oxide, magnesium L-glutamate, and the like. The copper compound includes copper sulfate, copper gluconate, and the like. The zinc compound includes zinc sulfate, zinc gluconate, zinc dioxide, and the like. The selenium compound includes selenocysteine, selenomethione, and the like. The calcium compound includes calcium chloride, calcium carbonate, calcium hydroxide, calcium lactate, calcium gluconate, calcium citrate, calcium L-glutamate, calcium pantothenate, calcium glycerophosphate, calcium 5'-ribonucleotide, calcium sulfate, tricalcium phosphate, calcium monohydrogenphosphate, calcium propionate, calcium dihydrogenphosphate, calcium dihydrogenpyrophosphate, calcium salt of carboxymethyl cellulose, calcium stearoyl lactate, calcium disodium ethylenediaminetetraacetate, calcined calcium of sea urchin shells, calcined calcium of sea shells, calcined calcium of bones, calcined calcium of coral, calcined calcium of milk sera, calcined calcium of eggshells, non-calcined calcium of sea shells, non-calcined calcium of bones, non-calcined calcium of coral, non-calcined calcium of pearl layer, non-calcined calcium of egg shells, high-degree bleaching powder, and the like.

The mineral composition of the inventive product may be used as it is, or it may be used as dry foods,

supplements, and liquid foods, such as soft drinks,
mineral water, luxury beverages and alcoholic beverages,
and the like. In addition, as for the pharmaceuticals,
the mineral composition is added to tablets, powders,
5 granules, drinks, and the like, and the mixture is formed
into preparation for use. In addition, the mineral
composition may be used in combination with essential
oils, amino acids, vitamins and other ingredients.
Particularly, the combined use of the mineral composition
10 and vitamins is effective in improvement of metal taste of
the fruits and the processed products thereof. The
content of the mineral in the mineral composition is not
particularly limited, and the content thereof in the
composition, calculated as a metal element, is preferably
15 from 0.0001 to 99.9% by weight, more preferably from 0.01
to 99.9% by weight.

The theanine contained in the mineral composition may
be any of L-form, D-form, and DL-form. Among them, the
L-form is preferable because its improvement of the effect
20 of the metal taste is high.

Since the theanine is highly safe, its content in the
composition is not particularly limited. The content of
the theanine differs depending upon the strength of the
metal taste. Concretely, in order that the mineral
25 composition sufficiently exhibits its effects, the content

of the theanine preferably ranges from 10^{-3} to 10^6 , more preferably from 10^{-1} to 10^5 , still more preferably from 10^{-1} to 10^4 , per 1 of the metal content in the mineral composition in a weight ratio. From the viewpoint of exhibiting the effects resulting from the formulation of the theanine, the content is preferably 10^{-3} or more, and in consideration of the amount of the mineral to be contained in the mineral composition, the content is 10^6 or less.

Since the theanine is formulated in the mineral composition, astringent taste, bitter taste, sour taste, salty taste, pungent taste, puckery taste, hot taste, and the like owned by the conventional mineral composition are modified.

The method for preparing the mineral composition of the present invention is not particularly limited, and examples thereof include a method comprising mixing minerals with theanine in a powder; a method comprising dissolving minerals and theanine in a solvent, such as water, to yield a mixed solution; a method comprising freeze-drying the resulting mixed solution; a method comprising spray-drying the mixed solution, and the like.

The present invention will be described in further detail by means of the following working examples and test examples, but the present invention is by no means limited

to these working examples.

Example 1

Glutaminase in an amount of 0.3 U per 1 ml of the
5 buffer was added to boric acid buffer (disodium
borate-sodium hydroxide, pH 11) containing 0.3 M glutamine
and 1.5 M ethylamine, and the mixture was incubated at
30°C for 22 hours to react the components. Two-hundred
and twenty-five millimoles of theanine was isolated from
10 1 L of the reaction mixture. Incidentally, a by-product,
glutamic acid, was 20 mmol. Theanine was isolated and
purified from the reaction mixture by applying the
reaction mixture to a Dowex 50x8, Dowex 1x2 column
chromatography and eluting with ethanol.

15 The isolated substance was applied to amino acid
analyzer-paper chromatography. From the fact that the
isolated substance exhibited the same behavior as standard
substance of theanine, there was confirmed that the
isolated substance is theanine. When the isolated
20 substance was hydrolyzed with hydrochloric acid or
glutaminase, glutamic acid and ethylamine were formed at a
molar ratio of 1:1. Since the isolated substance was
hydrolyzed with glutaminase, it was shown that ethylamine
was bound to glutamic acid at the γ -position. In
25 addition, from the results of the reaction of glutamic

acid formed by hydrolysis with glutamic acid dehydrogenase (GLuDH), there was confirmed that glutamic acid is L-form. From this finding, there was confirmed that the isolated substance is L-theanine.

5

Example 2

Ten kilograms of tea leaves (*Camellia sinensis* L.) were extracted with boiling water. The resulting extract was applied to a cation exchange resin ("Dowex HCR W-2," manufactured by Muromachi Kagaku Kogyo K.K.), and eluted with 1 N NaOH. The eluted fraction was applied to an activated carbon ("Taiko Kasseitan SG" manufactured by Futamura Kagaku Kogyo K.K.), and eluted with 15% EtOH, to give an eluted fraction. The resulting eluted fraction was concentrated using an RO membrane (Nitto Denko "NTR 729 HF"), and then purified by column chromatography, to give a purified product. Furthermore, the purified product was recrystallized, to give 24.8 g of L-theanine.

20 Test Example 1

In order to confirm the safety of L-theanine obtained in Examples 1 and 2, each of 3 week-old young female rats (7 rats/group) was orally administered with 1 ml of a 20% aqueous solution of theanine (inventive product), per 25 100 g of body weight with a probe, once a day, for 28

days. The rats of the control group were administered with 1 ml of water, per 100 g of body weight with a probe. The body weights of the rats were measured before administration, and 7, 14, 21 and 28 days after the administration. The results are shown in Figure 1. As shown in Figure 1, the growth suppression could not be observed, and dead cases were not confirmed by the administration of the inventive product.

Test Example 2

The effect of the obesity suppression of the inventive product on rats was tested. Each of L-theanine obtained in Example 1 and Example 2 was dissolved in 1 ml water (inventive product) at 20 mg per 1 body weight of 10 week-old ovariectomized rats (7 rats/group). Each of the rats was orally administered with a probe once a day for 28 days. The rats were fed freely with high sucrose diet, and given free access to drinking water. The rats of the control group were administered with 1 ml of water with a probe. The body weights of the rats were measured before administration, and 7, 14, 21 and 28 days after the administration. After the end of the administration periods, the rats were dissected, and the weights of their visceral fats and sera cholesterol levels were measured.

The results of the weight are shown in Figure 2. As shown

in Figure 2, the body weight increase in menopausal disorders was remarkably suppressed by the administration of the inventive product. In addition, the results of the weight of visceral fats and the sera cholesterol level are shown in Table 1.

Table 1

	Amount of Visceral Fats (g)	Sera Cholesterol Level (mg/dl)
Control	18.73 ± 1.37	93.18 ± 14.7
Administration of Inventive Product	7.50 ± 0.6	60.06 ± 21.57

Example 3

Iron lactate and L-theanine obtained in Example 1 were mixed in a mixing ratio of 4:1, to give a granular inventive product.

Example 4

Zinc sulfate and L-theanine obtained in Example 2 were mixed in a mixing ratio of 1:40. To 3 parts of the resulting composition was added 17 parts of water, to prepare a mixed aqueous solution. The mixed aqueous solution was spray-dried, to give a granular inventive

product.

Example 5

Magnesium sulfate and L-theanine obtained in Example 1 were mixed in a mixing ratio of 1:1000. To 5 parts of the resulting composition was added 15 parts of water, to prepare a mixed aqueous solution. The mixed aqueous solution was spray-dried, to give a granular inventive product.

Test Example 3

The inventive product was tested on the suppressive effect of the anxiogenic symptoms in humans. The test was performed on six subjects selected from among individuals who were accustomed to take about 6 cups or more of coffee daily, and were categorized in the high-anxiety group by the MAS method for evaluating the degree of manifested anxiety [Taylor, Abe, Takaishi; "Manifest Anxiety Scale (MAS) Instruction Manual", Sankyo Shobo, 1968]. In the test, an aqueous solution of the composition having the suppressive effect of the anxiogenic symptoms was prepared by dissolving 50 mg of L-theanine as obtained in Example 1 in 100 g of mineral water (hereinafter referred to as "anxiogenic symptoms-suppressive composition water") (equivalent to about 0.8 mg/kg). Each subject was

requested to drink the anxiogenic symptoms-suppressive composition water three times daily, and after 2 weeks, the degree of anxiety was again evaluated by the MAS method. As a result of drinking the anxiogenic symptoms-suppressive composition water for 2 weeks, 5 out of the 6 subjects were categorized in the low-anxiety group and 1 subject categorized in the moderate-anxiety group, demonstrating amelioration in the symptoms.

Test Example 4

Each of male and female subjects consisting of a total of 7 members was given a beverage prepared by dissolving the L-theanine obtained in Examples 1 and 2 at amounts of 0 mg, 60 mg, 300 mg or 1200 mg in 100 g of coffee extract in boiling water (equivalent to about 1 mg/kg, about 5 mg/kg, and about 200 mg/kg, respectively) 10 times per day for one month. The results thereof are shown in Table 2.

Table 2

Theanine Content				
	0 mg	60 mg	300 mg	1200 mg
High-Anxiety Group	4	2	0	0
Moderate-Anxiety Group	3	3	1	0
Low-Anxiety Group	0	2	0	7

As shown in Table 2, the number of subjects complaining to be in the high-anxiety group and the moderate-anxiety group decreased in accordance with the increase in the amount of administration of theanine.

Example 6

Theanine-containing candies were prepared with the composition shown in Table 3 by using the L-theanine prepared in Example 1. Incidentally, the content of the L-theanine in candies was measured, and as a result, the content was found to be 89.6 mg/g.

Table 3 Theanine-Containing Candies

1.	Granulated Sugar	64 parts
2.	Malt Syrup	23 parts
3.	L-Theanine	10 parts
4.	Flavor (Lemon Flavor)	0.05 parts
5.	50% Tartaric acid	1 part
6.	Water	30 parts

Ingredient 1 was dissolved completely in 20 parts of water, with heating to 110°C. Ingredient 3 was dissolved in the remaining water, and the mixture and Ingredient 2 were added. The temperature of the mixture was raised to 145°C. After the stove was turned off, Ingredient 5 was added thereto, and mixed. The mixture was cooled to 75° to 80°C, formed with a forming roller, to prepare theanine-containing candies.

Example 7

A theanine-containing blueberry beverage was prepared with the composition shown in Table 4 by using the L-theanine prepared in Example 2. Incidentally, the L-theanine in the blueberry beverage was quantified, and as a result, the content was found to be 98.3 mg/100 ml.

Table 4 Theanine-Containing Blueberry Beverage

1.	Isomerized Sugar	12 parts
2.	Blueberry Concentrated Fruits Juice	1.0 part
3.	1/5 Transparent Lemon Juice	0.4 parts
4.	Sodium Citrate	0.05 parts
5.	50% Sodium Citrate (Crystalline)	for pH adjustment
6.	L-Theanine	0.1 parts
7.	Flavor (Blueberry Flavor)	0.07 parts
8.	Water	Balance

Ingredients 1 to 4, 6 and 8 were dissolved by stirring. The pH of resulting mixture was adjusted to 3.1 with Ingredient 5, and thereafter the mixture was heated to 95°C. After adding Ingredient 7 to the mixture, the resulting mixture was filled and cooled, to prepare a theanine-containing blueberry beverage.

A theanine-containing grapefruits beverage was prepared with the composition shown in Table 5 by using the L-theanine prepared in Example 2. Incidentally, the L-theanine in the grapefruits was quantified, and as a result, the content was found to be 96.4 mg/100 ml.

Table 5 Theanine-Containing Grapefruits Beverage

1.	Isomerized Liquid Sugar	6	parts
2.	L-Theanine	0.1	parts
4.	Ferric Pyrophosphate	0.06	parts
5.	Placenta Extract	0.01	parts
6.	100% Grapefruits Juice	30	parts
7.	Sodium Citrate	for pH adjustment	
8.	Flavor (Grapefruits Flavor)	0.05	parts
9.	Water	Balance	

Ingredients 1 to 6, and 9 were dissolved by stirring. The pH of resulting mixture was adjusted to 3.1 with Ingredient 7, and thereafter the mixture was heated to 95°C. After adding Ingredient 8 to the mixture, each of 50 ml of the mixture was filled and cooled, to prepare a theanine-containing grapefruits beverage.

Test Example 5

A test for assessing the premenstrual syndrome-suppressive effect of the inventive product was performed in 20 women complaining of 5 or more premenstrual syndrome symptoms. The inventive product used herein was powdered L-theanine as prepared in Example

1. Each subject was requested to measure her basal body temperature upon awaking for 2 months. During the second month, 50 mg of powdered L-theanine per day was taken whenever a PMS-suggesting symptom developed during the corpus lutea stage from the day of suspected ovulation to the first day of menstruation in reference to the data compiled during the first month. During the test period, physical symptoms, mental symptoms and social symptoms were recorded in detail everyday. On the first day of the third menstruation, the test was terminated and a questionnaire survey was conducted. The questionnaire and results thereof are shown below.

Questionnaire Survey Concerning Premenstrual Syndrome of
Test Example 5

1. Were PMS symptoms suppressed ?

1) having remarkable effects; 2) having some effects; 3) having slight effects; 4) none.

2. For those selected 1), 2) or 3) in 1., were there any improvements in the daily life ?

1) improved to almost the same level as normal;

2) improved;

3) slightly improved;

4) none.

3. For those selected 1), 2) or 3) in 1., please
give specifics:

5 - Physical symptoms:

- Mental symptoms:

- Social symptoms:

10

Questionnaire Results of Test Example 5

1. Were PMS symptoms suppressed ?

1) having remarkable effects	6 subjects (30%);
2) having some effects	8 subjects (40%);
3) having slight effects	6 subjects (30%);
4) none	0 subjects (0%).

15

2. For those selected 1), 2) or 3) in 1., were
there any improvements in the daily life ?

20

1) improved to almost the same level as normal	4 subjects (20%);
2) improved	7 subjects (35%);
3) slightly improved	8 subjects (40%);
4) none	1 subject (5%).

25

3. For those selected 1), 2) or 3) in 1., please
give specifics:

Physical symptoms:

smooth body action, stiff shoulders healed,
light-headedness, sleepiness disappeared,
awaking in good humor, slept well, legs do not
swell, not become drowsy, breast discomfort
modified, bowel movement improved, allergy
mitigated, appetite being the same as usual.

Mental symptoms:

able to relax, became cheerful, able to take
positive attitude, became less irritable, became
less worrisome.

Social symptoms:

able to concentrate on job, finding the job less
burdensome, came to feel at ease.

Test Example 6

The inventive product was tested on the suppressive
effect of the premenstrual syndrome in 20 women
complaining of 3 or more symptoms of premenstrual
syndrome. The test was carried out for about 2 months,
and the first day of menstruation was defined as day 1.
The first month was a control period. During the second
month, the test was carried out for each of 10 subjects

being given 2 pieces of the theanine-containing candies prepared in Example 6 or 2 pieces of placebo from the last day of the second menstruation. Each candy was taken at a certain time everyday. During the test period, physical symptoms, mental symptoms and social symptoms were recorded in detail everyday. On the first day of the third menstruation, the test was terminated and a questionnaire survey was conducted. The questionnaire and results thereof are shown below.

Questionnaire Survey Concerning Premenstrual Syndrome of Test Example 6

1. Were PMS symptoms suppressed by the intake of candy?

- 1) having remarkable effects; 2) having some effects; 3) having slight effects; 4) none.

2. For those selected 1), 2) or 3) in 1., were there any improvements in the daily life ?

- 1) improved to almost the same level as normal;
2) improved;
3) slightly improved;
4) none.

Questionnaire Results of Test Example 6

1. Were PMS symptoms suppressed by the intake of the candy ?

5		1) having remarkable effects	2) having some effects	3) having slight effects	4) None
10	Theanine Candy	3	3	4	0
	Placebo	0	0	3	7

2. For those selected 1), 2) or 3) in 1., were there any improvements in the daily life ?

		1) equivalent to normal level	2) improved	3) slightly improved	4) None
20	Theanine Candy	4	3	3	0
25	Placebo	0	0	2	8

Test Example 7

The inventive product was tested on the suppressive effect of the premenstrual syndrome in 20 women

30 complaining of 5 or more symptoms of premenstrual syndrome. The test was carried out for about 2 months, and the first day of menstruation was defined as day 1. The first month was a control period. During the second month, the test was carried out for each of 10 subjects
35 being given 200 ml of the theanine-containing blueberry

beverage prepared in Example 7 or 200 ml of placebo from the last day of the second menstruation. Each beverage was taken at a certain time everyday. During the test period, physical symptoms, mental symptoms and social symptoms were recorded in detail everyday. On the first day of the third menstruation, the test was terminated and a questionnaire survey was conducted. The questionnaire and results thereof are shown below.

10 Questionnaire Survey Concerning Premenstrual Syndrome of Test Example 7

1. Were PMS symptoms suppressed by the intake of blueberry beverage ?

15 1) having remarkable effects; 2) having some effects; 3) having slight effects; 4) none.

2. For those selected 1), 2) or 3) in 1., were there any improvements in the daily life ?

20 1) improved to almost the same level as normal;
2) improved;
3) slightly improved;
4) none.

25 Questionnaire Results of Test Example 7

1. Were PMS symptoms suppressed by the intake of the beverage ?

		1) having remarkable effects	2) having some effects	3) having slight effects	4) None
5					
10	Theanine Beverage	4	4	2	0
	Placebo	0	0	2	8

2. For those selected 1), 2) or 3) in 1., were there any improvements in the daily life ?

		1) equivalent to normal level	2) improved	3) slightly improved	4) None
20	Theanine Beverage	5	2	3	0
	Placebo	0	0	1	9

As shown in the results of Test Examples 5, 6 and 7, there could be confirmed that theanine has an extremely high effect for suppressing PMS symptoms.

Test Example 8

Male and female panelists consisting of a total of 10 members were subjected to a sensory test with a 0.1% aqueous solution of a mineral composition using the inventive product obtained in Example 3 or with a 0.08%

aqueous solution of iron lactate. Their metal taste was ranked into five levels as 5: strong; 4: somewhat strong; 3: some metal taste; 2: slightly metal taste; and 1: no metal taste. The results are shown in Table 6.

Table 6

	0.1% Aqueous Solution of Mineral Composition	0.08% Aqueous Solution of Iron Lactate
Rank of Metal Taste	1.2	3.9

As shown in the results of Table 6, in the case of the supplemented mineral composition, favorable results can be obtained.

Test Example 9

Male and female panelists consisting of a total of 10 members were subjected to a sensory test with a 0.04% mineral composition-supplemented yogurt using the inventive product obtained in Example 4 or with a 0.001% zinc sulfate-supplemented yogurt. Their metal taste was ranked into five levels as 5: strong; 4: somewhat strong; 3: some metal taste; 2: slightly metal taste; and 1: no

metal taste. The results are shown in Table 7.

Table 7

5		0.04% Mineral Composition- Supplemented Yogurt	0.001% Zinc Sulfate- Supplemented Yogurt
10	Rank of Metal Taste	1.3	4.5

As shown in the results of Table 7, in the case of the supplemented mineral composition, favorable results can be obtained.

Test Example 10

Male and female panelists consisting of a total of 10 members were subjected to a sensory test with a 0.2% mineral composition-supplemented milk using the inventive product obtained in Example 5 or a 0.0002% magnesium sulfate-supplemented milk. Their metal taste was ranked into five levels as 5: strong; 4: somewhat strong; 3: some metal taste; 2: slightly metal taste; and 1: no metal taste. The results are shown in Table 8.

Table 8

5		0.2% Mineral Composition- Supplemented Milk	0.001% Magnesium Sulfate- Supplemented Milk
10	Rank of Metal Taste	1.2	4.7

As shown in the results of Table 8, in the case of the supplemented mineral composition, favorable results can be obtained.

Example 8

The following raw materials were mixed and tableted, to prepare a theanine-containing mineral supplement:

theanine (trade name: "SUNTHEANINE" manufactured by Taiyo Kagaku Co., Ltd.) 0.5% by weight, zinc acetate 3.0% by weight, crystalline cellulose 6.0% by weight, reductive maltose 20.0% by weight, lactose 65.0% by weight, Aspartame 1.0% by weight, sucrose fatty acid ester 4.0% by weight, and silicon dioxide 0.5% by weight.

Example 9

Twenty panelists were subjected to a sensory test for the theanine-containing mineral supplement prepared in

Example 8 and the theanine non-containing supplement. The taste was ranked into five levels with respect to four items, wherein 5 was the best, the rank being expressed as an average value of 20 members. The results are shown in Table 9. As a result, there is obtained an effect of reduction of bitter taste of the mineral in the theanine-containing mineral supplement.

Table 9

	Theanine-Containing Composition	Theanine Non-Containing Composition
Bitter Taste	3.8	2.8
Astringent Taste	4.1	1.9
Metal Taste	4.5	2.0
Overall Rank	4.3	2.2

Example 10

Ten women subjects complaining about their sensitivity to cold were requested to take two tablets of a theanine-containing capsule (200 mg/capsule) when they felt cold. The temperature of the tip finger was measured afterwards, and questionnaire survey was conducted. The same test was conducted to the placebo group, and a

comparison was made therebetween. The results of the questionnaire survey are shown in Table 10, and the temperature variation of the tip finger is shown in Figure 3.

Table 10

	Inventive Product Group	Placebo Group
Insensitive to cold in hands or feet	9	1
Body felt warm	5	0

Example 11

Ten ICR male mice were each orally administered with 10 ml of a 1% by weight theanine aqueous solution, per 1 kg of body weight, and the mice were allowed to stand in an inhalation box. The administered group of mice were compared with the 10 non-administered group of mice, wherein the amount of exercise was evaluated by counting the number of rotations of the rotatable cage for 60 minutes. The results are shown in Figure 4. As shown in the figure, a significant decrease in the amount of exercise was found by the administration of theanine.

Example 12

To 10 week-old ovariectomized rats (7 rats/group) was applied a foot shock electric stress (0.3 mA) once a day. In addition, one hour before applying the electric stress, the rats were orally administered with 2 mg or 20 mg of theanine per 1 kg of body weight in the form of an aqueous solution by using a probe. The rats of the control group were administered with 1 ml of water by using a probe. Such an electric shock was applied to rats for 7 days. On the day following the final electric stress-applying day, sodium pentobarbital was intraperitoneally administered in an amount of 50 mg/kg, and the sleeping time was measured. The results for the theanine-administered group, the non-applied group, and non-administered group are respectively shown in Figure 5.

It could be confirmed that the sleep disorders in menopause was suppressed by the administration of the theanine composition.

Example 13

Two-hundred and thirty-one women patients diagnosed as menopausal disorders took one theanine-containing capsule (200 mg/capsule) per day. The dose period was set to be 28 days. The degree of improvement in the menopausal disorders were evaluated by doctors and

patients, respectively. The results are shown in Tables 11 and 12.

Table 11 (Judgment by Patients)

Impression of Patients	Response Ratio (%)
Excellent	25.1
Good	68.4
No changes	6.5
Worse	0
Level of not less than "good"	93.5

Table 12 (Judgment by Doctors)

5	Impression of Doctors	Response Ratio (%)
	Remarkable Effect	13.9
	Effect	42.0
	Slight Effect	38.1
10	No changes	6.1
	Worse	0.0
	Level of not less than "effect"	55.8
15	Level of not less than "slight effect"	93.9

EQUIVALENTS

Those skilled in the art will be able to recognize or ascertain, many equivalents to the specific embodiments of the invention described in the present specification by using simple routine experimentation. Such equivalents are intended to be encompassed in the scope of the following claims.

INDUSTRIAL APPLICABILITY

The theanine-containing composition of the present invention has effects of suppression or amelioration to a plurality of the kinds of diseases, specifically to symptoms accompanying diminished homeostasis, such as

5 obesity, anxiogenic symptoms, premenstrual syndrome, sensitivity to cold, menopausal disorders, sleep disorders and autonomic imbalance. Moreover, since the composition of the present invention comprises theanine as an active ingredient, its safety is high, and the composition is

10 administered easily. In addition, the mineral composition of the present invention has a reduced peculiar metal taste, and the intake of the minerals can be made easily by the use of the inventive product.

CLAIMS

1. A composition for suppressing or ameliorating a
symptom accompanying diminished homeostasis, comprising
5 theanine.
2. The composition according to claim 1, wherein the
symptom accompanying diminished homeostasis is one or more
selected from the group consisting of obesity, anxiogenic
10 symptoms, premenstrual syndrome, sensitivity to cold,
menopausal disorders, sleep disorders and autonomic
imbalance.
3. The composition according to claim 1 or 2, wherein
15 the composition is a food composition or a pharmaceutical
composition.
4. The composition according to any one of claims 1 to
3, further comprising a mineral.
- 20
5. The composition according to claim 4, wherein the
mineral is one or more selected from the group consisting
of iron, magnesium, copper, zinc, selenium, calcium,
potassium, manganese, chromium, iodine, molybdenum,
25 nickel, vanadium, and salts thereof.

6. A mineral composition comprising theanine and a mineral.

7. The mineral composition according to claim 6, wherein
5 the mineral is one or more selected from the group
consisting of iron, magnesium, copper, zinc, selenium,
calcium, potassium, manganese, chromium, iodine,
molybdenum, nickel, vanadium, and salts thereof.

ABSTRACT

The present invention relates to a composition for suppressing or ameliorating a symptom accompanying diminished homeostasis, comprising theanine; and a mineral composition comprising theanine and a mineral. According to the present invention, there can be provided a composition for suppressing or ameliorating the above symptoms; and a mineral composition having a reduced peculiar metal taste, of which administration is made easily.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5

PLEASE NOTE:
YOU MUST
COMPLETE THE
FOLLOWING: ↓

COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT AND DESIGN APPLICATIONS

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert Title: → COMPOSITION COMPRISING THEANINE

Fill in Appropriate
Information —
For Use →
Without
Specification
Attached:

the specification of which is attached hereto. If not attached hereto,

the specification was filed on _____ as
United States Application Number _____;
and amended on _____ (if applicable); and/or
the specification was filed on February 23, 1999 as PCT
International Application Number PCT/JP99/00784; and was
amended under PCT Article 19 on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

Insert Priority
Information: →
if appropriate)

<u>10-57470</u> (Number)	<u>Japan</u> (Country)	<u>February 23, 1998</u> (Month / Day / Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<u>10-142119</u> (Number)	<u>Japan</u> (Country)	<u>May 8, 1998</u> (Month / Day / Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<u>10-234968</u> (Number)	<u>Japan</u> (Country)	<u>August 6, 1998</u> (Month / Day / Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<u>10-330207</u> (Number)	<u>Japan</u> (Country)	<u>November 5, 1998</u> (Month / Day / Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No

Insert Provisional
Application(s): →
(if any)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application:

Insert Requested
Information: →
(if appropriate)

Country	Application Number	Date of Filing (Month / Day / Year)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Insert Prior U.S.
Application(s): →
(if any)

(Application Number)	(Filing Date)	(Status — patented, pending, abandoned)
(Application Number)	(Filing Date)	(Status — patented, pending, abandoned)

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorney identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Raymond C. Stewart	(Reg. No. 21,066)	Terrell C. Birch	(Reg. No. 19,382)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slattery	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Mutter	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr.	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joe McKinney Muncy	(Reg. No. 32,334)	C. Joseph Faraci	(Reg. No. 32,350)
Donald J. Daley	(Reg. No. 34,313)	John W. Bailey	(Reg. No. 32,881)
John A. Castellano	(Reg. No. 35,094)		

Send Correspondence to: **BIRCH, STEWART, KOLASCH & BIRCH, LLP**
P.O. Box 747 • Falls Church, Virginia 22040-0747
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

**PLEASE NOTE:
YOU MUST
COMPLETE
THE
FOLLOWING:**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First or
Sole Inventor:
Insert Name of
Inventor →
Insert Date This
Document is Signed
Insert Residence →
Insert Citizenship
Insert Post Office →
Address

GIVEN NAME Tomoko	FAMILY NAME UEDA	INVENTOR'S SIGNATURE <i>Tomoko Ueda</i>	DATE* Oct. 1, 1999
Residence (City, State & Country) Yokkaichi-shi, Mie 510-0825 Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Taiyo Kagaku Co., Ltd. 9-5, Akahorishinmachi, Yokkaichi-shi, Mie 510-0825 Japan			

Full Name of Second
Inventor, if any:
see above

GIVEN NAME Yukiko	FAMILY NAME NAGATO	INVENTOR'S SIGNATURE <i>Yukiko Nagato</i>	DATE* Oct. 1, 1999
Residence (City, State & Country) Yokkaichi-shi, Mie 510-0825 Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Taiyo Kagaku Co., Ltd. 9-5, Akahorishinmachi, Yokkaichi-shi, Mie 510-0825 Japan			

Full Name of Third
Inventor, if any
see above

GIVEN NAME Yukiko	FAMILY NAME TANAKA	INVENTOR'S SIGNATURE <i>Yukiko Tanaka</i>	DATE* Oct. 1, 1999
Residence (City, State & Country) Yokkaichi-shi, Mie 510-0825 Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Taiyo Kagaku Co., Ltd. 9-5, Akahorishinmachi, Yokkaichi-shi, Mie 510-0825 Japan			

Full Name of Fourth
Inventor, if any
see above

GIVEN NAME Tsutomu	FAMILY NAME OKUBO	INVENTOR'S SIGNATURE <i>Tsutomu Okubo</i>	DATE* Oct. 1, 1999
Residence (City, State & Country) Yokkaichi-shi, Mie 510-0825 Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Taiyo Kagaku Co., Ltd. 9-5, Akahorishinmachi, Yokkaichi-shi, Mie 510-0825 Japan			

Full Name of Fifth
Inventor, if any
see above

GIVEN NAME Kanari	FAMILY NAME KOBAYASHI	INVENTOR'S SIGNATURE <i>Kanari Kobayashi</i>	DATE* Oct. 1, 1999
Residence (City, State & Country) Yokkaichi-shi, Mie 510-0825 Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Taiyo Kagaku Co., Ltd. 9-5, Akahorishinmachi, Yokkaichi-shi, Mie 510-0825 Japan			

I hereby appoint the following attorneys to prosecute this application and/or an international application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the attorney who first sent the application papers to the attorney notified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Raymond C. Stewart (Reg. No. 21,066)	Terrell C. Birch (Reg. No. 19,382)
Joseph A. Kolasch (Reg. No. 22,463)	James M. Slattery (Reg. No. 28,380)
Bernard L. Sweeney (Reg. No. 24,448)	Michael K. Mutter (Reg. No. 29,680)
Charles Gorenstein (Reg. No. 29,271)	Gerald M. Murphy, Jr. (Reg. No. 28,977)
Leonard R. Svensson (Reg. No. 30,330)	Terry L. Clark (Reg. No. 32,644)
Andrew D. Meikle (Reg. No. 32,868)	Marc S. Weiner (Reg. No. 32,181)
Joe McKinney Muncy (Reg. No. 32,334)	C. Joseph Faraci (Reg. No. 32,350)
Donald J. Daley (Reg. No. 34,313)	John W. Bailey (Reg. No. 32,881)
John A. Castellano (Reg. No. 35,094)	

Send Correspondence to: **BIRCH, STEWART, KOLASCH & BIRCH, LLP**
P.O. Box 747 • Falls Church, Virginia 22040-0747
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

**PLEASE NOTE:
YOU MUST
COMPLETE
THE
FOLLOWING:**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First or
Sole Inventor:
Insert Name of
Inventor
Insert Date This
Document is Signed

Insert Residence
Insert Citizenship

Insert Post Office
Address

Full Name of Second
Inventor, if any:
see above

Full Name of Third
Inventor, if any:
see above

Full Name of Fourth
Inventor, if any:
see above

Full Name of Fifth
Inventor, if any:
see above

GIVEN NAME Nobuyuki	FAMILY NAME AOI	INVENTOR'S SIGNATURE <i>Nobuyuki Aoi</i>	DATE* Oct. 1, 1999
Residence (City, State & Country) Yokkaichi-shi, Mie 510-0825 Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Taiyo Kagaku Co., Ltd. 9-5, Akahorishinmachi, Yokkaichi-shi, Mie 510-0825 Japan			
GIVEN NAME Seiji	FAMILY NAME SHU	INVENTOR'S SIGNATURE <i>Seiji Shu</i>	DATE* Oct. 1, 1999
Residence (City, State & Country) Yokkaichi-shi, Mie 510-0825 Japan		CITIZENSHIP Japan	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Taiyo Kagaku Co., Ltd. 9-5, Akahorishinmachi, Yokkaichi-shi, Mie 510-0825 Japan			
GIVEN NAME Lekh Raj	FAMILY NAME JUNEJA	INVENTOR'S SIGNATURE <i>Lekh Juneja</i>	DATE* Oct. 1, 1999
Residence (City, State & Country) Yokkaichi-shi, Mie 510-0825 Japan		CITIZENSHIP India	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Taiyo Kagaku Co., Ltd. 9-5, Akahorishinmachi, Yokkaichi-shi, Mie 510-0825 Japan			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			